Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY

Alnylam Pharmaceuticals — American Neurological Association Annual Meeting 2014

18 slides from Alnylam Pharmaceuticals's conference presentation, Oct 13, 2014

  1. Slide 1: Phase 2 Open-Label Extension Study of Patisiran

    Phase 2 Open-Label Extension Study of Patisiran An RNAi Therapeutic for the Treatment of Familial Amyloidotic Polyneuropathy American Neurological Association Annual Meeting October 13, 2014

  2. Slide 2: RNA Interference (RNAi): A New Class of Innovative Medicines

    RNA Interference (RNAi) A New Class of Innovative Medicines RNAi Therapeutics  Harness natural pathway » Catalytic mechanism » Mediated by small interfering RNA or “siRNA”  Therapeutic gene silencing » Any gene in genome » Distinct mechanism of action vs. other drug classes » Unique opportunities

  3. Slide 3: Patisiran (ALN-TTR02) Familial Amyloidotic Polyneuropathy (FAP)

    Patisiran (ALN-TTR02) Familial Amyloidotic Polyneuropathy (FAP) Patisiran in clinical development  International Nonproprietary Name designation for ALN-TTR02 = Patisiran (Pa-TEE-sa-ran)  Orphan drug status in US/EU  Fast track designation by FDA  Administered by IV infusion  Positive Phase 1 r

  4. Slide 4: Patisiran Phase 2 OLE Study Design

    Patisiran Phase 2 OLE Study Design OLE OLE OLE OLE OLE Dose 1 Dose 2 Dose 3 Dose 4 0 (out to 2 years) W1 W2 W3 W1 W2 W3 W1 W2 W3 W1 W2 W3 0 W1 W2 W3 0 Patisiran dosing: 0.30 mg/kg IV q3w 0 Serum TTR levels d 0, 1, 3, 7, 17, 84, 168, 182, 231, 232… mNIS+7, other clinical measures every 6mo d 0 (basel

  5. Slide 5: Patisiran Phase 2 OLE Preliminary Study Results: Demographics

    Patisiran Phase 2 OLE Preliminary Study Results Demographics Characteristic Result Number of patients N=27 (includes 11 patients in cardiac subgroup) Median age 64.0 years (range 29-77) Gender 18 males, 9 females TTR genotype • Val30Met (V30M) = 20 • Tyr116Ser (Y116S) = 1 • Ser77Tyr (S77Y) = 2 • Phe

  6. Slide 6: Patisiran Phase 2 OLE Preliminary Study Results: Baseline Characteristics

    Patisiran Phase 2 OLE Preliminary Study Results Baseline Characteristics Characteristic N Mean (range) Serum TTR (µg/mL) 27 245.6 (154.6 – 339.9) NIS (max impairment: 244) 27 34.8 (4.0 - 93.4) mNIS+7 (max impairment: 304) 26 52.1 (2.0-122.5) 10-meter walk test (sec) 22 10.1 (4.6-22.0) Hand grip stre

  7. Slide 7: Safety and Tolerability - TEAEs Related or Possibly Related

    Patisiran Phase 2 OLE Preliminary Study Results Safety and Tolerability - TEAEs Related or Possibly Related 0.30 mg/kg q3w (N=27) Severity Preferred Term N (%) Infusion-related reaction (IRR) 4 (14.8%) Mild Flushing 4 (14.8%) Mild Diarrhea 2 (7.4%) Mild-Moderate Peripheral Edema 2 (7.4%) Mild Ectrop

  8. Slide 8: Serum TTR Lowering

    Patisiran Phase 2 OLE Preliminary Study Results Serum TTR Lowering Mean % 1.0 0 Day N Knockdown Pre-dose Post-dose 0.9 1 25 21.4 3 25 46.8 0.8 20 % Mean Serum TTR Knockdown 7 25 71.1 Relative to Baseline (SEM) 0.7 17 24 77.8 0.6 84 23 77.1 40 0.5 168 20 79.1 182 17 87.6 0.4 60 231 3 81.7 0.3 232 3 8

  9. Slide 9: Neuropathy Impairment Scores

    Neuropathy Impairment Scores mNIS+7 Used in FAP Trials (304 points) 300 Postural BP or HRdb (2) Σ 5 NCS (10) Reflexes (20) NIS (244 points) Higher score indicates worsening of disease QST (80) Reflexes (20) Sensation (32) Motor strength/weakness Motor strength/weakness (192) (192) 0 BP: Blood Pressu

  10. Slide 10: Change in mNIS+7 at Months (N=19)

    Patisiran Phase 2 OLE Preliminary Study Results Change in mNIS+7 at 6 Months (N=19) 125 Change from Baseline to Month 6 100 mNIS+7 Mean Δ Median Δ SEM Total -0.95 0.00 2.59 mNIS+7 (points) 75 NIS-weakness 0.08 0.00 1.53 50 NIS-reflexes -0.39 0.00 0.43 QST -0.68 -2.00 1.82 25 NCS Σ5 0.11 0.00 0.15 Po

  11. Slide 11: Change in mNIS+7 by Stabilizer Use

    Patisiran Phase 2 OLE Preliminary Study Results Change in mNIS+7 at 6 Months (N=19) By Stabilizer Use 125 125 Patisiran + Stabilizer 100 100 mNIS+7 (points) mNIS+7 (points) Patisiran 75 75 50 50 25 25 0 0 0 1 2 3 4 5 6 0 1 2 3 4 5 6 Months on treatment Months on treatment Each line represents an ind

  12. Slide 12: Change in NIS at Months (N=20)

    Patisiran Phase 2 OLE Preliminary Study Results Change in NIS at 6 Months (N=20) 100 90 Change from Baseline to Month 6 80 NIS Mean Δ Median Δ SEM 70 NIS (points) 60 Total 0.22 -0.38 1.39 50 40 NIS-Weakness 0.24 0.00 1.49 30 NIS-Sensation 0.78 1.00 0.60 20 NIS-Reflexes -0.80 0.00 0.56 10 0 0 1 2 3 4

  13. Slide 13: Comparison of ΔNIS and ΔmNIS+7 Across FAP Studies

    Patisiran Phase 2 OLE Preliminary Study Results Comparison of ΔNIS and ΔmNIS+7 Across FAP Studies Natural History Natural History Tafamidis Fx1A- Diflunisal (linear)~ (nonlinear)# 201* Phase 3+ Mean (SEM) 8.9 ± 5.7 10.3 ± 5.7 PBO: 8.7 ± 2.0 PBO: 7.4 ± 6.9 D mNIS+7 at 6 mos.^ Drug: 2.5 ± 2.9 Drug: 2.

  14. Slide 14: Changes in Other Clinical Assessments

    Changes in Other Clinical Assessments Baseline Month 6 Δ Baseline to Month 6† Assessments N Mean (SEM) Mean (SEM) Mean (SEM) 10-Meter Walk^ (sec) 15 10.6 (1.2) 9.6 (0.9) -1.0 (0.4) Hand Grip Strength (kg) 22 25.0 (2.7) 24.3 (2.5) -0.70 (1.0) EQ-5D (max. impairment: 0) 20 0.77 (0.03) 0.77(0.03) - 0.0

  15. Slide 15: Patisiran Phase 2 OLE Summary

    Patisiran Phase 2 OLE Preliminary Study Results Summary  Chronic dosing with q3 weekly patisiran well tolerated in FAP patients, including patients on concurrent tetramer stabilizers » 282 doses administered to date, median of 11 doses/patient » Mean treatment duration of 7 months, longest treatmen

  16. Slide 16: Phase 3 Trial of Patisiran in FAP

    Phase 3 Trial of Patisiran in FAP Study Ongoing Randomized, double-blind, placebo-controlled, global study  Sample size and randomization » N=200 » 2:1, Patisiran vs. placebo  Key eligibility criteria » V30M and non-V30M FAP » Baseline FAP stages 1 and 2  Treatment regimen » Patisiran 0.30 mg/kg

  17. Slide 17: Acknowledgments

    Acknowledgments Patisiran (ALN-TTR02) Phase 2 Investigators  David Adams  Marcia Waddington-Cruz » CHU Hospital Bicetre, Le Kremlin- » Hospital Universitário, Rio de Janeiro, Bicetre, France Brazil  Ole Suhr  Hartmut Schmidt » Umea University Hospital, Umea, » University Hospital of Muenster, Sw

  18. Slide 18: Thank You

    Thank You www.alnylam.com

Alnylam Pharmaceuticals — American Neurological Association Annual Meeting 2014 on 6ix